Diabetic Retinopathy Market By Device Type (Focal Laser Treatment, Scatter Laser Treatment, Vitrectomy Devices), Drug Type (Aflibercept, Bevacizumab,Fluocinolone, Acetonide, Ranibizumab, Triamcinolone Acetonide) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Diabetic retinopathy is among the leading causes of legal blindness among the working-age adults worldwide. Anticipated increase in prevalence of diabetes prevalence indicates that diabetic retinopathy will continue to the prevalence of vision loss in the future. Diabetes and diabetes related complications carry heavy economic burden. Estimates also suggest that diabetic retinopathy alone contributes 10% to 42% of direct medical costs, whereas the indirect costs could be much higher. Surgical treatments have been preferred for a long time for diabetic retinopathy treatment at severe stages. Several pharmacological treatments are introduced and many are in development for treating this complication. This report studies the global and regional markets for various diabetic retinopathy treatments currently available.

For the purpose of this study, the global diabetic retinopathy market is assessed for diabetic retinopathy treatment devices and drugs. The devices market is categorized into focal laser treatment, scatter laser treatment and vitrectomy devices. the diabetic retinopathy treatment drugs is studied for aflibercept (Eylea), bevacizumab (Avastin), fluocinolone acetonide (Iluvien), ranibizumab (Lucentis) and triamcinolone acetonide. Global market size and forecast for the mentioned segments for the period 2014-2022 along with corresponding CAGRs for the forecast period 2016-2022 are included in this section.

Geographically, the global diabetic retinopathy market is studied for the following regional markets:

North America

a.    U.S.

b.    Canada

Europe

a.    U.K.

b.    Germany

c.    Rest of Europe

Asia-Pacific

a.    Japan

b.    China

c.    Rest of Asia-Pacific

Middle East and Africa

Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 for the mentioned segments are also presented in this study.

Qualitative information sets such as market dynamics (drivers, challenges, future prospects) and market inclination insights are provided in this market assessment report. Tools such as competition assessment and attractive investment proposition are also included in this study for studying the global market competition. The report concludes with company profiles section that highlights key information about the major market players operating in the global diabetic retinopathy market.

Diabetic Retinopathy Market

This report on diabetic retinopathy categorizes the drugs segment into:

  • Aflibercept (Eylea)
  • Bevacizumab (Avastin)
  • Fluocinolone acetonide (Iluvien)
  • Ranibizumab (Lucentis)
  • Triamcinolone acetonide 

Diabetic Retinopathy Market

In cases of diabetic macular edema, which can occur at any stage of diabetic retinopathy injections of anti-VEGF agents are administered to patients directly into the eye to prevent formation of new blood vessels at the back of the eye. Chief medicines used are ranibizumab and aflibercept. These drugs not only efficiently manage diabetic macular edema, but also are also instrumental in vision improvement. Other intravitreal treatments for diabetic macular edema are Fluocinolone intravitreal implant (Iluvien), Bevacizumab (Avastin) and Triamcinolone acetonide injections. Iluvien form Alimera Sciences, Inc. received FDA approval in 2014 for treating diabetic macular edema in patients who have been previously treated with corticosteroids and did not witness significant rise in intraocular pressure. The drug is also been under trial for treatment of dry age-related macular degeneration.

Based on geographical segmentation, the global Diabetic Retinopathy market is studied for:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Latin America
  • Middle East and Africa

 

Diabetic Retinopathy Market

Gradual rise in prevalence of diabetes and escalating diagnosis of diabetes related complications, favorable reimbursement policies and early introduction of breakthrough treatment modalities are the chief drivers that have allowed North America a dominant position in the diabetic retinopathy market. Extensive penetration of patented drugs such as Lucentis, Eylea, Iluvien and Avastin in the U.S. market has contributed to the clear leadership of North America in this area. Followed by North America, Europe is the second largest market for diabetic retinopathy due to high awareness in healthcare professionals and patients about effective management of diabetes related compilations and swift adoption of new treatments. Countries such as India and China while witnessing phenomenal growth in diabetes prevalence and improving rates of diagnosis will make Asia-Pacific the fastest progressing regional market for diabetic retinopathy treatment. Other factors contributing to the growth of this regional market are growth in healthcare expenditure, improving disposable income and development of healthcare infrastructure to facilitate medical tourism.

Choose License Type
Published Date:  Jun 2016
Category:  Medical Devices
Report ID:   57942
Report Format:   PDF
Pages:   120
Rating:    4.2 (50)
Connect With Us
+1-408-641-3282
24/7 Research Support